Home | SA Tuberculosis Vaccine Initiative

Final analysis of a trial of M72/AS01E vaccine to prevent Tuberculosis

The final analysis of a multi-site medical trial involving the University of Cape Town (UCT) has produced the first signal of a potentially effective vaccine against tuberculosis (TB) in almost 100 years.

Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy

The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.

RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

New multi-functional TB blood test validated

As part of a global research effort SATVI researchers have developed and validated a new, simple blood-based test to identify healthy people at risk of developing tuberculosis (TB) disease, and identify sub clinical or clinical TB.

World TB Day 2024: Yes! We can end TB

Join us in marking a pivotal moment in the battle against TB this World TB Day, March 24, 2024.

News from the South African Tuberculosis Vaccine Initiative.

Research Focus: Titan Vaccine Research Project

Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow the selection of the most promising TB vaccine candidates.

Shining a spotlight on science

SATVI's Professor Nemes and Doctor Young-Bailie recently participated in Soapbox Science co-hosted by the University of Cape Town (UCT), iThemba LABS, the South African Astronomical Observatory (SAAO), and the V&Alfred Waterfront.

Latest research: Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans

SATVI scholars have co-authored "Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans" appearing in the Frontiers in Immunology journal.